SEC Form 4 · accession 0002050172-26-000034
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Bernstein
Officer — President, R&D & CMO
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 2, 2026 | S | 4,481 | $26.376 | D | 15,519 | D | |
| Common StockF3 | Sep 2, 2026 | S | 625 | $27.1211 | D | 14,894 | D | |
| Common StockF4 | Sep 3, 2026 | S | 5,130 | $26.0133 | D | 9,764 | D | |
| Common Stock | Sep 3, 2026 | S | 59 | $25.78 | D | 9,705 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.